Drug interactions between abiraterone and Xofigo
|Xofigo (radium 223 dichloride)|
Interactions between your drugs
abiraterone ↔ radium 223 dichloride
Applies to:abiraterone and Xofigo (radium 223 dichloride)
Consumer information for this interaction is not currently available.
CONTRAINDICATED: The concomitant use of radium Ra 223 dichloride with abiraterone and prednisone/prednisolone may increase the risk of death and fractures in patients with metastatic castration-resistant prostate cancer (CRPC). Preliminary results of a phase III clinical trial involving this combination has reported an increased risk of mortality (34.7% vs 28.2%) and fractures (26% vs 8.1%) in patients receiving radium Ra 223 dichloride plus abiraterone and prednisone/prednisolone compared to patients treated with placebo and abiraterone and prednisone/prednisolone (n=405). It is unknown if enzalutamide (a second generation androgen receptor antagonist) can be effectively and safely used with radium Ra 223 dichloride.
MANAGEMENT: Until more information is available, use of radium Ra 223 dichloride with abiraterone and prednisone/prednisolone should be considered contraindicated. European and US authorities are prohibiting the start of new treatments with this combination and suspending use in patients currently receiving these drugs in combination in favor of other therapeutic alternatives. In addition, continued monitoring for fractures should be considered for patients previously treated with the combination. Preliminary evidence suggests that use of bone health agents such as bisphosphonates or denosumab may diminish the risk of fractures.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Bayer HealthCare Pharmaceuticals, Inc "Important Drug Warning: Xofigo. Available from: URL: https://hcp.xofigo-us.com/downloads/pdf/PP-600-US-3282%20Xofigo%20November%202017%20DHCP%20Letter%20-%20Digital%20Version.pdf." ([2017, Nov 30]):
- European Medicines Agency "Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone. Available from: URL: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Xofigo_20/Under_evaluation/WC500245467.pdf." ([2018, Mar 19]):
Drug and food interactions
Applies to: abiraterone
Taking abiraterone with food increases the amount of medicine that gets absorbed by the body. This may increase the risk of side effects such as high blood pressure, water retention, and a condition called hypokalemia (low blood potassium), which in severe cases can lead to muscle weakness, paralysis, breathing and swallowing difficulties (due to muscle paralysis), and irregular heart rhythm. You should take abiraterone once a day on an empty stomach. No food should be eaten for at least two hours before and one hour after taking abiraterone. Let your doctor know if you experience nausea, vomiting, constipation, abdominal cramping, confusion, dizziness, lightheadedness, fainting, muscle weakness, muscle cramps, numbness or tingling, rapid heart beat, chest pain, and/or swelling in the legs or feet, as these may be symptoms of hypokalemia or excessive effects of abiraterone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No therapeutic duplications were found for your selected drugs.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.